SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Aug 13 2009, 10:40 AM EST

CombinatoRx Gains Preclinical B-Cell Cancer Therapy from Clinical Data in $252M Deal

GEN News Highlights

Clinical Data licensed its preclinical candidate for B-cell cancers to CombinatoRx in a deal worth up to $252 million. CombinatoRx will initially develop this adenosine A_2A

The $252 million will be paid with the achievement of clinical, regulatory, and commercial milestones. Clinical Data will also receive royalties on product sales. While CombinatoRx will be responsible for further development, Clinical Data retains a co-development option, which is exercisable after review of Phase IIa results. 

Research has shown that a combination drug approach utilizing adenosine A_2A agonists could be beneficial in the treatment of multiple myeloma, according to the firms. Initial results have demonstrated broad activity in multiple myeloma cell lines, synergy with multiple myeloma standard-of-care therapies, potent induction of apoptosis, as well as selectivity and safety with a broad therapeutic window over normal cells, they explain.

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR